Drug intelligence / Profile preview

ActiGraft

Development stage: Unknown
Lead developer: RedDress
Administration: Topical

Overview

ActiGraft is an autologous point-of-care wound management system developed by RedDress. It utilizes a patient's own peripheral blood, mixed with a proprietary coagulation powder, to create an in vitro whole blood clot at the bedside. This clot is then applied to chronic, non-healing wounds, such as diabetic foot ulcers and pressure ulcers, where it acts as a protective scaffold and bioactive covering. By mimicking the body's natural coagulation process, ActiGraft reactivates the wound healing cascade, providing essential components like white blood cells, platelets, and fibrin to the wound site. The system received FDA clearance and CE Mark in 2020 and is eligible for Medicare reimbursement.

Brand names: ActiGraftActiGraft Pro
Other names: ActiGraft System

Beyond the preview

Go deeper on ActiGraft.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ActiGraft.

Explore the full profile